{
    "code": 0,
    "data": [
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 21 January 2026 post announcement of the financial results of the Company for the quarter and nine months ended 31 December 2025.",
            "news_id": "7db48c03-3170-415a-8aa9-9bfdeb4a9443",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=98590399-a1e5-4850-b1d1-7dc5a0e0624c.pdf",
            "news_date": "2026-01-24 11:19:07",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Link of Audio Recording of the Earning call held on Wednesday 21 January 2026 at 05:00 p.m. (IST) is attached.",
            "news_id": "33afea00-37eb-4dc6-8383-f7b57bc891f9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=006d77e4-a46d-437f-bea4-75bf9ebf9b33.pdf",
            "news_date": "2026-01-21 18:54:57",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the Quarter and Nine Months ended 31 December 2025.",
            "news_id": "bb7dc070-45e2-4b01-8b26-e349eb2ba63f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9f2c09b5-05e5-4855-a958-c87b55f93e94.pdf",
            "news_date": "2026-01-21 16:10:10",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine Months Ended On 31 December 2025",
            "news_body": "Enclosed",
            "news_id": "1eeae038-3dd2-42bc-b39b-086093168d2e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7675a64a-847f-4adc-932a-352bb723d809.pdf",
            "news_date": "2026-01-21 15:56:08",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 31 October 2025 post announcement of the financial results of the Company for the quarter and half year ended 30 September 2025.",
            "news_id": "45315886-4a96-406e-8a7c-ff65b40310f3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1dff5871-12db-4395-b8d6-48b90f2bf81f.pdf",
            "news_date": "2025-11-04 12:16:44",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Link of Audio Recording of the Earnings call held on Friday 31 October 2025 at 05:00 p.m. (IST) is attached.",
            "news_id": "5ab90549-4234-49d5-a93f-a438e8028e71",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac3b457a-903c-4955-91bc-207a06c18e1b.pdf",
            "news_date": "2025-10-31 19:18:49",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter and half year ended 30 September 2025.",
            "news_id": "e8ef3ff1-3ee9-4cc9-a644-261f5b2d9770",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c5075fa5-d0b9-4bec-bb4d-be981ed10d47.pdf",
            "news_date": "2025-10-31 16:06:36",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended 30 September 2025",
            "news_body": "Enclosed",
            "news_id": "5120ca5b-c61d-4678-b0b4-911b5618cb91",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e1340d64-38d9-4e7b-803b-f5898aa60b87.pdf",
            "news_date": "2025-10-31 15:45:06",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 24 July 2025 post announcement of financial results of the Company for the quarter ended 30 June 2025.",
            "news_id": "0512a727-f2d4-4085-92e1-c16a96d7a6cc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=21cafcb0-5a4b-41bc-8bbd-d22bc1fe6a70.pdf",
            "news_date": "2025-07-28 14:49:39",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Link of Audio Recording of the Earnings call held on Thursday 24 July 2025 at 05:00 p.m. (IST) is attached.",
            "news_id": "a1333e37-84e1-496d-870e-efb4f0d89160",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0f802fc6-0fbb-4f42-8114-ca6c7452f35f.pdf",
            "news_date": "2025-07-24 19:09:41",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter ended 30 June 2025.",
            "news_id": "0e61fd3e-b78f-4101-94b0-8173bc56b5e8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=24014063-8902-49ca-9450-f324d81a0a06.pdf",
            "news_date": "2025-07-24 15:57:27",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended 30 June 2025",
            "news_body": "Enclosed",
            "news_id": "8efd88ea-304a-4c84-b469-0786fdf9f565",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7749674a-c617-494e-b16a-b1d19a155fd8.pdf",
            "news_date": "2025-07-24 15:40:26",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 05 May 2025 post announcement of the financial results of the Company for the quarter and financial year ended 31 March 2025.",
            "news_id": "17eca8ae-578a-49f1-bde3-466f6a5e9bd0",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aeb51fdb-77f9-4e5c-89d8-33753d794828.pdf",
            "news_date": "2025-05-09 16:25:03",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Link of Audio Recording of the Earning call held on Monday 05 May 2025 at 05:00 p.m. (IST) is attached.",
            "news_id": "e98923f4-bf5d-46ed-8c5e-f2772d6b3c1f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=59b96c3f-9d2c-461a-ae96-65c3ef70fbd8.pdf",
            "news_date": "2025-05-05 19:16:55",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter and financial year ended 31 March 2025.",
            "news_id": "387174d8-b512-4c66-bfdd-971dacc7ec9c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f7aae476-4c32-4e70-a456-8fb82cdd7450.pdf",
            "news_date": "2025-05-05 14:58:15",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Financial Year Ended On 31 March 2025",
            "news_body": "Enclosed",
            "news_id": "14a53d54-1cbb-4b11-b5e3-54419e3aac9e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9f2c0537-e8fa-44c5-8b21-424ab5af8d30.pdf",
            "news_date": "2025-05-02 17:20:19",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 28 January 2025 post announcement of financial results of the Company for the quarter and nine months ended 31 December 2024.",
            "news_id": "66864f20-649f-485d-846f-fea9c0ff7417",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7b42327e-9a70-445f-8a49-f9bd860d1944.pdf",
            "news_date": "2025-01-31 14:54:08",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the Quarter and Nine Months ended 31 December 2024.",
            "news_id": "ddc36c61-338e-4907-aabc-291a67de2aa6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ead540b7-c2c2-44bd-ba12-1f89811376a2.pdf",
            "news_date": "2025-01-28 16:01:46",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine Months Ended On 31 December 2024",
            "news_body": "Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended 31 December 2024",
            "news_id": "b2d27463-8814-465e-8611-2c09de9237fc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dc3f2266-5e11-411b-a1a1-06ad22e93223.pdf",
            "news_date": "2025-01-28 15:45:15",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 25 October 2024 post announcement of financial results of the Company for the quarter and half year ended 30 September 2024.",
            "news_id": "bf8f4067-c9aa-4f3f-925f-7f645a043af4",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=82d3233f-799f-430e-81f8-75f2f6a8fb2b.pdf",
            "news_date": "2024-10-30 14:10:16",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Link of Audio Recording of the Earnings call held on Friday, 25 October 2024 at 05:00 p.m. (IST) is attached.",
            "news_id": "a6a92a73-3821-4c74-bf12-813bd1d4b397",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8976706a-e3e0-43ce-9a3b-876c83a0ea05.pdf",
            "news_date": "2024-10-25 20:33:09",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the Quarter and Half Year ended 30 September 2024.",
            "news_id": "b399a638-9270-43c6-8798-7d6251afe64f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=230952b7-2976-435e-8b10-cc610808a8c8.pdf",
            "news_date": "2024-10-25 16:06:25",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended 30 September 2024",
            "news_body": "Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30 September 2024",
            "news_id": "a46a06fd-ac20-49e2-89b2-f132963f0da4",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=034efd0b-f963-450b-a938-7130f80a854e.pdf",
            "news_date": "2024-10-25 15:50:21",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 24 July 2024 post announcement  of  financial results of the Company for the quarter ended 30 June 2024.",
            "news_id": "38c564ab-ecf3-43bd-8cb1-81aab252241c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5d862cdf-2532-4ea7-bb38-1be24d65743b.pdf",
            "news_date": "2024-07-29 19:17:45",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Link of Audio Recording of the Earnings call held on Wednesday, 24 July 2024 at 05:00 p.m. (IST) is attached.",
            "news_id": "c340c9fa-926d-4983-b011-fe36f41a9321",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5793c877-1bd2-4564-8840-811565e86090.pdf",
            "news_date": "2024-07-24 20:32:49",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter ended 30 June 2024.",
            "news_id": "93256770-3887-4085-a4f1-a3c7ba3cd630",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=13a8e931-efb7-4c89-94a8-3aeb6d0d6ccd.pdf",
            "news_date": "2024-07-24 15:56:42",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended On 30 June 2024.",
            "news_body": "Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended on 30 June 2024.",
            "news_id": "6fae59b0-b996-41c8-9154-868f07c7341b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7bc30181-f7ca-456e-a04d-cc6b0b66b8d9.pdf",
            "news_date": "2024-07-24 15:39:55",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 03 May 2024 post announcement of the financial results of the Company for the quarter and financial  year ended 31 March 2024.",
            "news_id": "237797da-6cca-487f-adcd-433501aaddec",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e715b9d7-9e22-45cc-8083-6f98413e2d3a.pdf",
            "news_date": "2024-05-07 12:50:56",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor  Presentation for the quarter and financial year ended 31 March 2024.",
            "news_id": "d783112e-dc82-4f77-8126-98c5866dfdd3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=25ccc1b3-d263-4754-ac58-9db7d969432f.pdf",
            "news_date": "2024-05-03 16:00:25",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Financial Year Ended On 31 March 2024",
            "news_body": "Audited Financial Results (Standalone and Consolidated) Of The Company For the Quarter And Financial Year Ended On 31 March 2024.",
            "news_id": "0deff1fa-ab93-42ee-87fc-c29302fd92e7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a57bfa99-d5fc-473b-a556-17d6d5d363ca.pdf",
            "news_date": "2024-05-03 15:41:25",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 20 January 2024 post announcement of financial results of the Company for the quarter and nine months ended 31 December 2023.",
            "news_id": "7836e465-52fc-4d17-9d63-d819d842e51b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8247c09f-eef8-463e-9803-dbc31dc80ba5.pdf",
            "news_date": "2024-01-24 17:28:37",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the Quarter and Nine Months Ended 31 December 2023.",
            "news_id": "08f6a038-1734-4eb4-82d0-0009138f92e9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bfd06438-7391-46a6-85ae-be8325f42f26.pdf",
            "news_date": "2024-01-20 15:33:41",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine Months Ended On 31 December 2023",
            "news_body": "Unaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Nine Months ended on 31 December 2023",
            "news_id": "733feb59-deec-4084-ad62-516f81fdc78d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a198ff4f-d4ac-4837-915a-b484c47d69ce.pdf",
            "news_date": "2024-01-20 15:26:22",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 02 November 2023 post announcement of financial results of the Company for the quarter and half year ended 30 September 2023",
            "news_id": "84e278f4-9553-4d24-99c6-f6c31611959a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9adf0e68-8c94-4cfe-82c9-75ec6542c85e.pdf",
            "news_date": "2023-11-07 16:53:29",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the Quarter and Half Year ended 30 September 2023.",
            "news_id": "e9c17520-2041-492b-a1d7-fc311dcc3fa9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6f75a0c4-9a31-4881-a117-e4529e77326d.pdf",
            "news_date": "2023-11-02 17:06:58",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended On 30 September 2023",
            "news_body": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended On 30 September 2023<BR>",
            "news_id": "bc231248-3234-4a6d-a0d4-5912432a0ba9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a7309991-d90b-46f6-865c-94737ec209b9.pdf",
            "news_date": "2023-11-02 15:57:00",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Board Meeting Outcome For Outcome Of The Board Meeting Held On 02.11.2023",
            "news_body": "Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30 September 2023.<BR> <BR> The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 02 November 2023.<BR> <BR> Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of SEBI Listing Regulations.<BR> <BR> The above information shall be made available on the website of the Company at www.tatvachintan.com.<BR> <BR> The Board meeting commenced at 11:45 A.M. and concluded at 03:35 P.M.",
            "news_id": "ba049c1f-7c6e-4940-ba53-c0bd33dae446",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fdc956a9-8e90-43bb-b95a-0c3848960f4e.pdf",
            "news_date": "2023-11-02 15:44:04",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 04 August 2023 post announcement of financial results of the Company for the quarter ended 30 June 2023",
            "news_id": "ccd2d46d-bc07-465d-892c-88277104e79c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2dbdfe35-ab4c-4aec-b59a-e7b9c2126251.pdf",
            "news_date": "2023-08-09 21:20:56",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter ended 30 June 2023",
            "news_id": "e452d245-52ae-4bd3-9957-39c4976f8bd2",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3b5ee3f7-f9ab-480e-b875-6ddb60e26c56.pdf",
            "news_date": "2023-08-04 16:03:38",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended On 30 June 2023",
            "news_body": "Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended on 30 June 2023",
            "news_id": "adb8e0f4-2c61-46b3-adb5-a54d43d2b5b2",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=765fd745-2d21-49e8-99c0-f44a82149aa2.pdf",
            "news_date": "2023-08-04 15:03:06",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on 05 May 2023 post announcement of financial results of the Company for the quarter and financial year ended 31 March 2023. The above information shall be made available on Company's website of at www.tatvachintan.com.",
            "news_id": "8c1b10fa-ad86-428f-9598-c0a691747adc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8bed5ca3-58fc-4a6e-85f8-761550cdad03.pdf",
            "news_date": "2023-05-10 14:52:20",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed Investor Presentation for the quarter and financial year ended 31 March 2023.\u00a0The above information shall be made available on the website of the Company at www.tatvachintan.com.",
            "news_id": "ad1ec11e-4e47-4c30-a185-0d562daf6c41",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d81047d8-a458-439b-9066-eef4973f5564.pdf",
            "news_date": "2023-05-05 16:49:37",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Financial Year Ended On 31 March 2023",
            "news_body": "Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter and Financial Year Ended On 31 March 2023",
            "news_id": "2f76a89f-5736-4341-866e-3e5d3e53329c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=19529b9a-fa9e-4c18-b1ee-c3bb8547b01a.pdf",
            "news_date": "2023-05-05 15:55:16",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On 05.05.2023",
            "news_body": "Outcome Of The Board Meeting Held On 05.05.2023",
            "news_id": "7e479c9b-14c9-4d6c-a738-14b3928e5745",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0e1ab9b9-5ce5-4e2f-bb52-dabfc286e4e3.pdf",
            "news_date": "2023-05-05 15:49:24",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on 24 January 2023 post announcement of financial results of the Company for the quarter and nine months ended 31 December 2022. The above information shall be made available on Company's website of at www.tatvachintan.com.",
            "news_id": "de6b83d4-8313-4ff6-a173-6815f5ba874f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=778a6786-8c6b-439a-951e-92e9c5eccb62.pdf",
            "news_date": "2023-01-30 17:02:39",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed Investor Presentation for the quarter and nine months ended 31 December 2022.\u00a0The above information shall be made available on the website of the Company at www.tatvachintan.com.",
            "news_id": "5887a07a-cc7d-4658-b19f-c6e693fa0819",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7627a661-9783-4a5e-a335-14bb566354fa.pdf",
            "news_date": "2023-01-24 16:14:39",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine Months Ended On 31 December 2022",
            "news_body": "Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2022.<BR> <BR> The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 24 January 2023.<BR> <BR> Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations.<BR> <BR> The above information shall be made available on the website of the Company at www.tatvachintan.com.<BR> <BR> The Board meeting commenced at 12:30 P.M. and concluded at 03:35 P.M.",
            "news_id": "f6caa8ec-c50d-489b-9974-3fd6122510e1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ec3ed94b-abe9-4760-8c8a-8d92ab043776.pdf",
            "news_date": "2023-01-24 15:52:57",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On 24.01.2023",
            "news_body": "Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2022.<BR> <BR> The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 24 January 2023.<BR> <BR> Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations.<BR> <BR> The above information shall be made available on the website of the Company at www.tatvachintan.com.<BR> <BR> The Board meeting commenced at 12:30 P.M. and concluded at 03:35 P.M.",
            "news_id": "4c091ef3-1f5f-47f7-a9e2-37866e0ef9f1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=df7880a2-d953-436b-a6da-39037553ef30.pdf",
            "news_date": "2023-01-24 15:48:37",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.",
            "news_body": "In terms of Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose disclosure of Related Party Transactions in the format specified under SEBI Circular bearing reference no. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated 22 November 2021, for the half year ended 30 September 2022.The above information shall be made available on the website of the Company at www.tatvachintan.com.",
            "news_id": "e2779910-4634-4c1c-aeb7-a2e4759fae83",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c6c74422-dcdc-4a18-b04b-3bf8c1c4fa47.pdf",
            "news_date": "2022-11-16 16:33:17",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on 04 November 2022 post announcement of financial results of the Company for the quarter and half year ended 30 September 2022. The above information shall be made available on Company's website of at www.tatvachintan.com.",
            "news_id": "9eb5a5b8-062a-4c9d-bb75-8891ad1efd69",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9d31c2b9-d5c8-44ee-b339-70b029d930f5.pdf",
            "news_date": "2022-11-08 14:19:39",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed Investor Presentation for the quarter and half year ended 30 September 2022. The above information shall be made available on the website of the Company at www.tatvachintan.com.",
            "news_id": "4d38f0ab-a49f-472e-bbab-3255c01f2a99",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3c70c60d-6d10-41c5-a7b7-171cdd56b3f9.pdf",
            "news_date": "2022-11-04 16:38:26",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended On 30 September 2022",
            "news_body": "Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30 September 2022.<BR> <BR> The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 04 November 2022.<BR> <BR> Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations.<BR> <BR> The above information shall be made available on the website of the Company at www.tatvachintan.com.<BR> <BR> The Board meeting commenced at 01:00 P.M. and concluded at 03:55 P.M.",
            "news_id": "76f102fe-f159-4337-b343-38b9867ba763",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=999953e3-9cdf-439c-b462-f4e0fd59f3e0.pdf",
            "news_date": "2022-11-04 16:15:07",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On 04.11.2022",
            "news_body": "Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30 September 2022.<BR> <BR> The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 04 November 2022.<BR> <BR> Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations.<BR> <BR> The above information shall be made available on the website of the Company at www.tatvachintan.com.<BR> <BR> The Board meeting commenced at 01:00 P.M. and concluded at 03:55 P.M.",
            "news_id": "794b3eee-730f-4ae5-9389-ccd43a212c57",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=939977ad-7cc2-45bb-a11c-7532aacf54c6.pdf",
            "news_date": "2022-11-04 16:10:52",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on 25 July 2022 post announcement of financial results of the Company for the quarter ended 30 June 2022. The above information shall be made available on Company's website of at www.tatvachintan.com.This is for your information and records.",
            "news_id": "71fc1c22-3bd9-4f56-83f3-010644a07fbe",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ae5fe1c9-9758-4553-b576-f3bfcedf249e.pdf",
            "news_date": "2022-07-29 11:34:36",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed Investor Presentation for the quarter ended 30 June 2022. The above information shall be made available on the website of the Company at www.tatvachintan.com.This is for your information and records.",
            "news_id": "99cc4a3c-51a4-4271-b6f7-ee61942258d1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5605c8a3-6517-4977-b734-c11ac57ad8bd.pdf",
            "news_date": "2022-07-25 16:23:36",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended On 30 June 2022",
            "news_body": "Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30 June 2022.<BR> <BR> The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 25 July 2022.<BR> <BR> Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations.<BR> <BR> The above information shall be made available on the website of the Company at www.tatvachintan.com.<BR> <BR> The Board meeting commenced at 11:30 A.M. and concluded at 03:30 P.M. <BR> <BR> Kindly take above intimation on your record and oblige.",
            "news_id": "f2e69554-0caa-4f39-a2a5-e79f9b2d30de",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3e76545e-8e4f-420b-808a-9fb50a48f42a.pdf",
            "news_date": "2022-07-25 15:44:04",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On 25.07.2022",
            "news_body": "Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30 June 2022.<BR> <BR> The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 25 July 2022.<BR> <BR> Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations.<BR> <BR> The above information shall be made available on the website of the Company at www.tatvachintan.com.<BR> <BR> The Board meeting commenced at 11:30 A.M. and concluded at 03:30 P.M. <BR> <BR> Kindly take above intimation on your record and oblige.",
            "news_id": "25e1dd8b-1d85-43c7-a205-734179ccebd3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=db1966d5-8e87-4ea5-b76c-a039689f9dc8.pdf",
            "news_date": "2022-07-25 15:40:47",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.",
            "news_body": "Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions for the half year ended 31 March 2022.The above information shall be uploaded on the website of the Company at www.tatvachintan.com.Kindly take the same on your record.",
            "news_id": "333d7c8b-0b6c-4f37-82b6-f5dd241c29d7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d9f80ff4-3bd3-401f-ad12-0280af1a89dc.pdf",
            "news_date": "2022-05-20 16:58:51",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on  25 April 2022 post announcement of financial results of the Company for the quarter and year ended 31 March 2022. The above information will also be hosted on Company's website of at www.tatvachintan.com.This is for your information and records.",
            "news_id": "06946ec3-b5f0-4b94-8bf3-24fbd954bad8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e7af8b2e-0e1d-4331-bb1d-5d8a778daf7e.pdf",
            "news_date": "2022-04-28 17:22:58",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed Investor Presentation for the quarter and year ended 31 March 2022. The above information is also being made available on the website of the Company at www.tatvachintan.com.This is for your information and records.",
            "news_id": "51bd7be7-30e8-46d8-a179-ddb97c86851c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2e0bbe9f-a9f7-465d-b13e-7fffda449cca.pdf",
            "news_date": "2022-04-25 19:31:36",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Year Ended On 31 March 2022",
            "news_body": "Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended on 31 March 2022",
            "news_id": "caf4ff66-1a7a-4232-8837-c44d99319eb7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f117c854-a8b0-48cb-a384-b54acfe7b71b.pdf",
            "news_date": "2022-04-25 15:46:49",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On 25.04.2022",
            "news_body": "Outcome Of The Board Meeting Held On 25.04.2022",
            "news_id": "fdc5a97e-36dc-49b5-a1e9-f464dd98c84a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3420afc4-19a9-4e15-938c-1d8fa011b5d5.pdf",
            "news_date": "2022-04-25 15:43:26",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on January 18, 2022 post announcement of financial results of the Company for the quarter and nine months ended December 31, 2021. The same will be uploaded on the Company''s website.This is for your information and records.",
            "news_id": "b038763c-6089-463c-981f-e130c105a50b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=975018b0-1235-4b89-9a50-17b436c86bde.pdf",
            "news_date": "2022-01-22 16:18:13",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "We hereby enclosed Investor Presentation for the quarter and nine months ended December 31, 2021. The same will be uploaded on the Company's website.<BR> <BR> This is for your information and records.",
            "news_id": "c3e0a3a2-df8f-4dfa-9b07-12c924527372",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=12007f95-3267-4ee1-a8fa-4cdb280c1890.pdf",
            "news_date": "2022-01-18 18:59:36",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financials Results For The Quarter And Nine Months Ended December 31, 2021",
            "news_body": "Unaudited Financials Results For The Quarter And Nine Months Ended December 31, 2021",
            "news_id": "39921e88-e714-4d2a-a71b-fe6479b19508",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=28f6c539-c2a4-4a7c-a313-f3a761e2a092.pdf",
            "news_date": "2022-01-17 17:40:13",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On January 17, 2022",
            "news_body": "Outcome of the Board Meeting held on January 17, 2022",
            "news_id": "7622f4da-0749-49b3-b698-bd0169e421c1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=87ad0c18-ed67-46d9-addf-3f4a0064a613.pdf",
            "news_date": "2022-01-17 17:31:26",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015<BR> as amended, please find enclosed herewith the transcript of the earnings call held on 25 October 2021<BR> post announcement of financial results of the Company for the quarter and half year ended 30 September<BR> 2021. The Transcript has been uploaded on the Company's website www.tatvachintan.com.<BR> This is for your information and records.",
            "news_id": "e11bf1fc-c503-4ce5-b6e9-a4889a0bad6f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=69abab09-4d33-4734-b55f-df16ff8b1b68.pdf",
            "news_date": "2021-10-29 18:05:04",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Consolidated And Standalone Financial Results For The Quarter And Half Year Ended 30 September 2021.",
            "news_body": "We are enclosing herewith, the un-audited consolidated and standalone financial results of the Company along with limited review report for the quarter and half year ended 30 September 2021, which have been approved and taken on record at a meeting of the Board of Directors of the Company held today.<BR> The above information is also available on the website of the Company: www.tatvachintan.com",
            "news_id": "fa63175e-f3dd-4a17-935d-aec26cf20438",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2ca3ce35-312f-4a93-8b30-3402ee7889f9.pdf",
            "news_date": "2021-10-23 15:12:38",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On 23 October 2021",
            "news_body": "We wish to inform that the Board of Directors of the Company at its meeting held today i.e., 23 October 2021, has approved the unaudited financial results of the Company (both standalone and consolidated) prepared in accordance with Indian Accounting Standards (IndAS) for the quarter and half year ended as on 30 September 2021. <BR> A copy of the said Financial Results together with Limited review report are enclosed herewith. <BR> The Board meeting commenced at 11.30 am and concluded at 3.00 pm.",
            "news_id": "e5fde7b3-5ce9-45a9-ba71-8256dfa7e8c9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=70ea360e-021f-4dc6-8e64-91886583ec83.pdf",
            "news_date": "2021-10-23 15:07:58",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "The transcript of the earnings call held on 16 August 2021 post<BR> announcement of financial results of the company for the quarter ended 30 June 2021 .",
            "news_id": "06864f89-ea7e-47bb-9067-35219dc9755e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=701348c6-ccaf-45c1-b4b3-11902caff13c.pdf",
            "news_date": "2021-09-01 17:51:06",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Submission Of Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended 30Th June, 2021",
            "news_body": "Submission of Un-audited Standalone and Consolidated Financial Results of the Company for the Quarter ended 30th June, 2021",
            "news_id": "4164565d-f8a7-435c-8b4d-6d599f3334c9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fdf65d6c-cae2-4d9d-9cf4-525d40e1484a.pdf",
            "news_date": "2021-08-14 17:47:39",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting Dated 14Th August, 2021 As Required Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
            "news_body": "1. Copy of the Limited Review Report of the Statutory Auditors of the Company, M/s. NDJ & Co, Chartered Accountants, (Firm Registration No. 136345W), on the Un-audited Consolidated Financial Results;<BR> 2. Copy of the Un-audited Consolidated Financial Results of the Company for the quarter ended 30th June, 2021 of the Current Financial Year 2021-22;<BR> 3. Copy of the Limited Review Report of the Statutory Auditors of the Company, M/s. NDJ & Co, Chartered Accountants, (Firm Registration No. 136345W), on the Un-audited Standalone Financial Results;<BR> 4. Copy of the Un-audited Standalone Financial Results of the Company for the quarter ended 30th June, 2021 of the Current Financial Year 2021-22;<BR>",
            "news_id": "91f3bb56-e225-4f92-b8a3-50134c05ef68",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cdb57fab-2b27-4e6b-a720-9e8894172d2f.pdf",
            "news_date": "2021-08-14 17:43:47",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting Dated 14Th August, 2021 As Required Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
            "news_body": "1. Copy of the Limited Review Report of the Statutory Auditors of the Company, M/s. NDJ & Co, Chartered Accountants, (Firm Registration No. 136345W), on the Un-audited Consolidated Financial Results;<BR> 2. Copy of the Un-audited Consolidated Financial Results of the Company for the quarter ended 30th June, 2021 of the Current Financial Year 2021-22;<BR> 3. Copy of the Limited Review Report of the Statutory Auditors of the Company, M/s. NDJ & Co, Chartered Accountants, (Firm Registration No. 136345W), on the Un-audited Standalone Financial Results;<BR> 4. Copy of the Un-audited Standalone Financial Results of the Company for the quarter ended 30th June, 2021 of the Current Financial Year 2021-22;<BR>",
            "news_id": "ef30fac1-4912-4868-b559-f5df3e4692c5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ec5eda8f-4305-41fc-a91d-cfc8ec475fe3.pdf",
            "news_date": "2021-08-14 17:43:04",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        }
    ],
    "remarks": ""
}